BioVie Inc.
Index- P/E- EPS (ttm)-9.05 Insider Own0.40% Shs Outstand24.98M Perf Week-11.81%
Market Cap65.00M Forward P/E- EPS next Y-2.37 Insider Trans1.99% Shs Float5.06M Perf Month-36.50%
Income-149.50M PEG- EPS next Q-0.42 Inst Own6.30% Short Float2.41% Perf Quarter-18.85%
Sales- P/S- EPS this Y-116.30% Inst Trans-8.04% Short Ratio3.19 Perf Half Y-55.44%
Book/sh0.40 P/B6.35 EPS next Y-39.10% ROA-694.80% Target Price13.67 Perf Year-82.35%
Cash/sh0.96 P/C2.65 EPS next 5Y- ROE- 52W Range2.51 - 19.10 Perf YTD-43.56%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-86.70% Beta2.33
Dividend %- Quick Ratio5.70 Sales past 5Y- Gross Margin- 52W Low1.20% ATR0.28
Employees6 Current Ratio5.70 Sales Q/Q- Oper. Margin- RSI (14)27.54 Volatility8.52% 8.56%
OptionableNo Debt/Eq0.00 EPS Q/Q-31.10% Profit Margin- Rel Volume0.47 Prev Close2.52
ShortableYes LT Debt/Eq1.16 Earnings- Payout- Avg Volume38.18K Price2.54
Recom1.70 SMA20-18.51% SMA50-33.34% SMA200-50.30% Volume18,131 Change0.79%
Jan-15-21Initiated B. Riley Securities Buy $47
Apr-25-22 08:00AM  
Mar-29-22 10:55AM  
Mar-10-22 08:00AM  
Mar-09-22 04:05PM  
Jan-20-22 08:00AM  
Jan-07-22 09:40AM  
Dec-28-21 08:00AM  
Dec-09-21 08:00AM  
Dec-01-21 08:00AM  
Nov-04-21 08:00AM  
Nov-01-21 08:00AM  
Oct-26-21 08:00AM  
Oct-13-21 08:00AM  
Sep-22-21 08:00AM  
Sep-15-21 04:01PM  
Aug-11-21 01:14PM  
Aug-08-21 09:28PM  
Aug-06-21 05:30PM  
Aug-05-21 08:00AM  
Jul-27-21 08:00AM  
Jul-22-21 08:00AM  
Jul-16-21 08:00AM  
Jun-29-21 08:00AM  
Jun-28-21 08:00AM  
Jun-25-21 08:00AM  
Jun-24-21 08:00AM  
Jun-23-21 08:00AM  
Jun-17-21 04:05PM  
Jun-11-21 08:00AM  
May-12-21 08:00AM  
May-10-21 08:19AM  
Apr-28-21 07:00AM  
Apr-27-21 04:05PM  
Mar-11-21 07:00AM  
Mar-09-21 07:00AM  
Feb-19-21 07:00AM  
Feb-02-21 08:30AM  
Oct-30-20 08:00AM  
Oct-29-20 08:00AM  
Sep-23-20 08:00AM  
Sep-21-20 07:00AM  
Sep-17-20 07:55PM  
Jun-16-20 08:30AM  
Jun-11-20 08:30AM  
Dec-09-19 08:00AM  
Oct-22-19 07:00AM  
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Santa Monica, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KIM JOANNE WENDYCFODec 07Buy5.402,00010,7982,000Dec 09 04:46 PM